John Scarlett

Bio:

Dr. John “Chip” Scarlett is a veteran biopharmaceutical CEO with more than 40 years of leadership in drug development, commercialization, and strategic transaction. Most recently, he was Chairman and CEO of Geron Corporation for nearly 14 years, transforming it into a commercial-stage company with the FDA and EU approvals of RYTELO®, and advancing a late-stage pipeline in hematologic malignancies.

Prior to Geron, Dr. Scarlett was President and CEO of Proteolix, where he oversaw the $851M acquisition by Onyx and the development of carfilzomib (KYPROLIS®), now a blockbuster therapy. He co-founded and led Tercica (acquired by Ipsen) and Sensus Drug Development (acquired by Pharmacia), successfully advancing INCRELEX® and SOMAVERT®. Earlier in his career, he founded Covance Biotechnology Services (acquired by Fujifilm) and held senior leadership roles at Novo Nordisk and Johnson & Johnson.